Literature DB >> 15464415

Gaucher disease: complexity in a "simple" disorder.

Ellen Sidransky1.   

Abstract

Gaucher disease, the recessively inherited deficiency of the enzyme glucocerebrosidase and the most common sphingolipidosis, has both non-neurological and neuronopathic forms and a continuum of diverse clinical manifestations. Studies of genotype-phenotype correlations reveal significant genotypic heterogeneity among clinically similar patients, and vastly different phenotypes among patients with the same mutations. The region surrounding the glucocerebrosidase gene (GBA) on chromosome 1q is particularly gene-rich, with a highly homologous pseudogene sequence 16 kb downstream. Recombination events within the GBA locus contribute to the etiology of some mutations in Gaucher disease. Studies of patients with Gaucher disease and atypical manifestations, including parkinsonism, myoclonic epilepsy, cardiac involvement and collodion skin, seek to define other genetic or environmental factors contributing to the phenotypes. Recent reports demonstrating an association between Gaucher disease and parkinsonism provide an example of heterozygosity for a Mendelian disorder acting as a risk factor for a complex disease. There are rare patients with Gaucher disease and differing genotypes who develop early onset, treatment-refractory parkinsonism. Neuropathology in a group of these patients showed alpha-synuclein-reactive Lewy bodies in brain regions specifically associated with Gaucher disease. Family studies of these probands suggested that the incidence of parkinsonism might be more frequent in obligate heterozygotes. In a complementary finding, the examination of GBA in autopsy samples from individuals with sporadic Parkinson disease identified alterations in the GBA sequence in 14% of the cohort. These studies provide evidence that altered glucocerebrosidase may contribute to a vulnerability to parkinsonism. Moreover, this research demonstrates how insights from rare, single gene disorders like Gaucher disease can provide a window into the etiology of more common, multifactorial genetic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464415     DOI: 10.1016/j.ymgme.2004.08.015

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  134 in total

1.  Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes.

Authors:  Zakarya El-Morsy; Mohamed T Khashaba; Othman El-Sayed Soliman; Sohier Yahia; Dina Abd El-Hady
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

Authors:  P Chérin; C Rose; C de Roux-Serratrice; D Tardy; D Dobbelaere; B Grosbois; E Hachulla; R Jaussaud; R-M Javier; E Noël; P Clerson; A Hartmann
Journal:  J Inherit Metab Dis       Date:  2010-06-02       Impact factor: 4.982

3.  Glucocerebrosidase mutations in diffuse Lewy body disease.

Authors:  Kenya Nishioka; Owen A Ross; Carles Vilariño-Güell; Stephanie A Cobb; Jennifer M Kachergus; David M A Mann; Julie Snowden; Anna M T Richardson; David Neary; Christopher A Robinson; Alex Rajput; Spiridon Papapetropoulos; Deborah C Mash; Rajesh Pahwa; Kelly E Lyons; Zbigniew K Wszolek; Dennis W Dickson; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2011-01       Impact factor: 4.891

4.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

5.  Applications of iPSC-derived models of Gaucher disease.

Authors:  Daniel K Borger; Elma Aflaki; Ellen Sidransky
Journal:  Ann Transl Med       Date:  2015-11

6.  Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening.

Authors:  Daniel J Urban; Wei Zheng; Ozlem Goker-Alpan; Ajit Jadhav; Mary E Lamarca; James Inglese; Ellen Sidransky; Christopher P Austin
Journal:  Comb Chem High Throughput Screen       Date:  2008-12       Impact factor: 1.339

7.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

8.  In silico and functional studies of the regulation of the glucocerebrosidase gene.

Authors:  Yotam N Blech-Hermoni; Shira G Ziegler; Kathleen S Hruska; Barbara K Stubblefield; Mary E Lamarca; Matthew E Portnoy; Eric D Green; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2009-11-04       Impact factor: 4.797

9.  Gaucher disease: resetting the clinical and scientific agenda.

Authors:  Pramod K Mistry; Neal J Weinreb; Roscoe O Brady; Gregory A Grabowski
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

10.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.